Advisors Preferred’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$801K Buy
+660
New +$674K 0.12% 112
2026
Q1
Sell
-550
Closed -$594K 256
2025
Q4
$594K Hold
550
0.1% 124
2025
Q3
$454K Sell
550
-2,850
-84% -$2.12M 0.07% 140
2025
Q2
$2.64M Hold
3,400
0.44% 56
2025
Q1
$2.74M Buy
+3,400
New +$2.83M 0.37% 54
2024
Q1
Sell
-13
Closed -$7.7K 240
2023
Q4
$7.7K Sell
13
-8
-38% -$4.67K ﹤0.01% 218
2023
Q3
$11.3K Sell
21
-979
-98% -$504K ﹤0.01% 173
2023
Q2
$461K Sell
1,000
-453
-31% -$190K 0.11% 74
2023
Q1
$510K Buy
+1,453
New +$490K 0.17% 50
2021
Q4
Sell
-1,808
Closed -$415K 208
2021
Q3
$415K Buy
1,808
+37
+2% +$9.13K 0.06% 105
2021
Q2
$409K Sell
1,771
-602
-25% -$121K 0.04% 129
2021
Q1
$440K Buy
2,373
+658
+38% +$129K 0.06% 106
2020
Q4
$284K Sell
1,715
-792
-32% -$118K 0.05% 132
2020
Q3
$371K Buy
2,507
+1,016
+68% +$157K 0.07% 79
2020
Q2
$243K Buy
+1,491
New +$229K 0.07% 69
2018
Q4
Sell
-678
Closed -$73K 175
2018
Q3
$73K Buy
+678
New +$67.8K 0.03% 113

Other funds holding LLY

Advisors Preferred's LLY Position: Q2 2026 in Review

Advisors Preferred opened a new position in Eli Lilly (LLY) in Q2 2026: 660 shares worth $801K. The stake represents 0.12% of the portfolio and ranks #112 among its holdings. This is a return to the name: Advisors Preferred previously reported a position in LLY as recently as Q4 2025.

Advisors Preferred first reported a position in LLY in Q3 2018 and has held it in 16 quarters since. The position peaked at $2.74M in Q1 2025. 4,601 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Advisors Preferred held 660 shares of Eli Lilly worth $801K as of Q2 2026.
  • Eli Lilly was a new Advisors Preferred position in Q2 2026.
  • Eli Lilly made up 0.12% of Advisors Preferred's portfolio in Q2 2026, its #112 holding.
  • Advisors Preferred first reported a position in Eli Lilly in Q3 2018 and has held it in 16 quarters since.
  • Advisors Preferred's Eli Lilly position peaked at $2.74M in Q1 2025.
  • 4,601 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Advisors Preferred's 13F filing for Q2 2026, filed 11 Aug 2026.